The intracameral cefuroxime/moxifloxacin debate

Article

A report from the Endophthalmitis symposia at ESCRS

Per Montan introduced delegates to his own unique critical look at the peer-reviewed journals which have covered the cefuroxime/moxifloxacin debate.

Whilst acknowledging that he had had five articles published himself which looked at the topic of cefuroxime, he wished to declare his neutrality on the subject as he was not a strong advocator of either.

Cefuroximne was introduced in the 70s and its mode of action is to target the cell walls. Moxifloxacin is the new contender on the block, having been around for just a decade.

The use of intracameral cefuroxime at the end of cataract surgery reduces the occurrence of postoperative endophthalmitis, according to the findings of a multicentre study carried out by the European Society of Cataract and Refractive Surgeons (ESCRS).These findings were published in the June issue of the Journal of Cataract & Refractive Surgery, following on from their first presentation at the 2006 ESCRS congress in London, UK.

The prospective, randomized, partially masked multicentre study enrolled 16,603 patients from 24 ophthalmology units in Austria, Belgium, Germany, Italy, Poland, Portugal, Spain, Turkey and the United Kingdom. The study was based on a 2×2 factorial design, with intracameral cefuroxime and topical perioperative levofloxacin factors resulting in four treatment groups.

A total of 29 patients presented with endophthalmitis, of whom 20 were classified as having proven infective endophthalmitis. The absence of an intracameral cefuroxime prophylactic regimen at 1 mg in 0.1 mL normal saline was associated with a 4.92-fold increase in the risk for total postoperative endophthalmitis. Furthermore, the use of clear corneal incisions, compared with scleral tunnels, was associated with a 5.88-fold increase in risk in infection, whilst the use of silicone intraocular lens (IOL) material compared with acrylic was associated with a 3.13-fold increased risk.

It was concluded that intracameral cefuroxime use can reduce the risk of developing postoperative endophthalmitis and that other risk factors include clear corneal incisions and the use of silicone IOLs.

“Alas, there is no data yet reported in any peer reviewed journal about moxifloxacin. I would therefore urge those of you out there who are using it to send in your data to the journals so we can learn more.”

A fuller report on Per Montan's critique will appear at a later date.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.